Matching articles for "Diamox"
Dichlorphenamide (Keveyis) for Periodic Paralysis
The Medical Letter on Drugs and Therapeutics • April 11, 2016; (Issue 1492)
Dichlorphenamide (Keveyis – Taro), an oral carbonic
anhydrase inhibitor, has been approved by the
FDA for treatment of primary hypokalemic and
hyperkalemic periodic paralysis and related...
Dichlorphenamide (Keveyis – Taro), an oral carbonic
anhydrase inhibitor, has been approved by the
FDA for treatment of primary hypokalemic and
hyperkalemic periodic paralysis and related variants.
Dichlorphenamide is the first drug to be approved in
the US for this indication. It was approved as Daranide
in 1958 for treatment of glaucoma, but had not been
marketed since 2002.
Advice for Travelers
The Medical Letter on Drugs and Therapeutics • June 1, 2012; (Issue 118)
Patients planning to travel to other countries often ask
for information about appropriate vaccines and prevention
of diarrhea and malaria. More detailed advice for
travelers is available from the Centers...
Patients planning to travel to other countries often ask
for information about appropriate vaccines and prevention
of diarrhea and malaria. More detailed advice for
travelers is available from the Centers for Disease
Control and Prevention (CDC) at www.cdc.gov/travel.
Guidelines are also available from the Infectious
Diseases Society of America (IDSA).
Drugs for Treatment of ADHD
The Medical Letter on Drugs and Therapeutics • May 1, 2011; (Issue 105)
Attention-deficit/hyperactivity disorder (ADHD) is a disruptive behavior disorder that occurs in about 5%
of school-age children, most often in boys, and frequently persists into young...
Attention-deficit/hyperactivity disorder (ADHD) is a disruptive behavior disorder that occurs in about 5%
of school-age children, most often in boys, and frequently persists into young adulthood.
Drugs That May Cause Psychiatric Symptoms
The Medical Letter on Drugs and Therapeutics • December 15, 2008; (Issue 1301)
Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment could also be due to the underlying illness, previously...
Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment could also be due to the underlying illness, previously unrecognized psychopathology, or psychosocial factors. The withdrawal of some drugs can cause symptoms such as anxiety, psychosis, delirium, agitation or depression.
Click here to view the free full article.
Click here to view the free full article.
Advice for Travelers
The Medical Letter on Drugs and Therapeutics • May 1, 2004; (Issue 21)
Patients planning to travel to other countries often ask physicians for advice about immunizations and prevention of diarrhea and malaria. More detailed advice for travelers is available from the Centers for...
Patients planning to travel to other countries often ask physicians for advice about immunizations and prevention of diarrhea and malaria. More detailed advice for travelers is available from the Centers for Disease Control (CDC) at 877-FYI-TRIP (877-394-8747) or www.cdc.gov/travel. Recommendations for the treatment of parasitic diseases are available in the public reading room of The Medical Letter's web site.
Drugs That May Cause Psychiatric Symptoms
The Medical Letter on Drugs and Therapeutics • July 8, 2002; (Issue 1134)
Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment may also be due to the underlying illness, previously...
Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment may also be due to the underlying illness, previously unrecognized psychopathology, or psychosocial factors. The withdrawal of some drugs can cause symptoms such as anxiety, psychosis, delirium, agitation or depression.
Advice for Travelers
The Medical Letter on Drugs and Therapeutics • April 15, 2002; (Issue 1128)
Patients planning to travel to other countries often ask physicians for advice about immunizations and prevention of diarrhea and malaria. More detailed advice for travelers is available from the CDC at...
Patients planning to travel to other countries often ask physicians for advice about immunizations and prevention of diarrhea and malaria. More detailed advice for travelers is available from the CDC at 877-FYI-TRIP (877-394-8747) or www.cdc.gov/travel.
Drugs that may cause Cognitive Disorders in the Elderly
The Medical Letter on Drugs and Therapeutics • November 27, 2000; (Issue 1093)
Older patients are especially susceptible to drug-induced cognitive impairment. They are more likely to be taking multiple drugs, to have higher blood levels of those drugs because of renal or hepatic...
Older patients are especially susceptible to drug-induced cognitive impairment. They are more likely to be taking multiple drugs, to have higher blood levels of those drugs because of renal or hepatic dysfunction, and to have pre-existing cognitive problems that make it difficult to detect the role of drugs causing new symptoms or making old ones worse.
A Topical Prostaglandin for Glaucoma
The Medical Letter on Drugs and Therapeutics • November 8, 1996; (Issue 987)
Lantaoprost, a prostaglandin F2-alpha analog, has been approved by the FDA for topical treatment of elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension refractory to other...
Lantaoprost, a prostaglandin F2-alpha analog, has been approved by the FDA for topical treatment of elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension refractory to other drugs.
A Topical Carbonic Anhydrase Inhibitor For Glaucoma
The Medical Letter on Drugs and Therapeutics • September 1, 1995; (Issue 956)
Dorzolamide hydrochloride (Trusopt - Merck), a thienothio-pyran-2-sulfonamide carbonic anhydrase inhibitor, was recently approved by the US Food and Drug Administration in a 2% ophthalmic solution for...
Dorzolamide hydrochloride (Trusopt - Merck), a thienothio-pyran-2-sulfonamide carbonic anhydrase inhibitor, was recently approved by the US Food and Drug Administration in a 2% ophthalmic solution for treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
High Altitude Sickness
The Medical Letter on Drugs and Therapeutics • September 4, 1992; (Issue 878)
Rapid exposure to altitudes more than 8,000 feet above sea level can cause serious medical problems. Since the last Medical Letter article on this subject (Vol. 30, page 89, 1988), some new information on...
Rapid exposure to altitudes more than 8,000 feet above sea level can cause serious medical problems. Since the last Medical Letter article on this subject (Vol. 30, page 89, 1988), some new information on prevention and treatment of these disorders has been reported.
High Altitude Sickness
The Medical Letter on Drugs and Therapeutics • September 23, 1988; (Issue 775)
Rapid exposure to altitudes more than 8,000 feet above sea level can cause serious medical problems. Some new approaches to prevention and treatment of these disorders have recently been...
Rapid exposure to altitudes more than 8,000 feet above sea level can cause serious medical problems. Some new approaches to prevention and treatment of these disorders have recently been reported.